Hemolytic Anemia in a Glucose-6-Phosphate Dehydrogenase-Deficient Patient Receiving Hydroxychloroquine for COVID-19: A Case Report.
Perm J
; 242020.
Article
in English
| MEDLINE | ID: covidwho-922950
ABSTRACT
INTRODUCTION:
The growing coronavirus disease 2019 (COVID-19) pandemic initially led to widespread use of hydroxychloroquine sulfate as an off-label experimental treatment of this disease. CASE PRESENTATION Acute hemolytic anemia developed in an African American man with COVID-19-related pneumonia and glucose-6-phosphate dehydrogenase (G6PD) deficiency who completed the standard 5-day experimental course of hydroxychloroquine. Although the trigger leading to our patient's hemolytic sequelae will never be known with certainty, his clinical course suggests that hydroxychloroquine use and/or COVID-19 infection may trigger hemolysis in susceptible patients with G6PD deficiency.DISCUSSION:
This case confirms recent findings that the potential risks of hydroxychloroquine therapy for COVID-19 may outweigh the benefits.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Enzyme Inhibitors
/
COVID-19
/
Glucosephosphate Dehydrogenase Deficiency
/
Hydroxychloroquine
/
Anemia, Hemolytic
Type of study:
Case report
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
/
Male
/
Middle aged
Language:
English
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS